Cagrilintide vs Semaglutide: Why It Is Really a Combo, Not a Versus (2026)

The honest one-line answer: this is not a fair fight, and it is not even really a versus. Semaglutide is an FDA-approved GLP-1 medicine you can be prescribed today; cagrilintide is an investigational amylin analog that is rarely run alone and is almost always studied combined with semaglutide as CagriSema. To see where both sit among every option, our roundup of the best peptides for weight loss is the hub above this comparison. So the real question is not "which one wins" but "is adding cagrilintide to semaglutide worth it," and the trials say the combination beats either drug alone.

Most "cagrilintide vs semaglutide" pages set the two up as rivals. Our first-party data shows why that framing is wrong: among ProtocolPlus users who track cagrilintide, about 42% also track semaglutide, because they are running CagriSema, not choosing between them. This page settles the question two ways at once: what the REDEFINE-1 trial actually shows for cagrilintide alone, semaglutide alone, and the combination, and what our community actually does, which is mostly use them together. For the full science on either molecule, we link up to its dedicated guide so this page stays a clean decision hub.

Key Takeaways

• It is a combo, not a versus. Cagrilintide is mostly run WITH semaglutide as CagriSema, not against it. In our data about 42% of cagrilintide users also track semaglutide (roughly 1,532 people), the single most telling signal on this page. A usage signal, not proof either is better for you.
• The combination wins on weight loss. In the Phase 3 REDEFINE-1 trial, CagriSema produced about 22.7% mean weight loss at 68 weeks, versus about 16.1% for semaglutide alone and about 11.8% for cagrilintide alone (placebo ~2.3%).
• Cagrilintide alone is the weakest option. On its own it lost about 11.8% in REDEFINE-1 and about 10.8% in an earlier Phase 2 trial, below semaglutide. Its value is as an add-on, not a standalone.
• Semaglutide is the only approved, prescribable choice here. It is FDA-approved (Wegovy for weight, Ozempic for type 2 diabetes); cagrilintide is investigational and not approved, with only research-grade solo supply.
• Mechanisms are complementary, not competing. Semaglutide is a GLP-1 receptor agonist; cagrilintide is an amylin analog. Two different appetite pathways, which is exactly why the combination outperforms either alone.
• Tolerability is GI-dominant for both, with cagrilintide a touch gentler in our reports (nausea ~38% vs ~44%); the combination concentrates both drugs' GI effects.

Cagrilintide vs semaglutide at a glance

Here is the side-by-side before we go deep. The pattern is clear: semaglutide leads on everything you can actually get and prove today, while cagrilintide's real strength only shows up when it is added to semaglutide. Everything below this table explains the why.

The table is the headline, and the row that matters most is the trial one: cagrilintide alone trails semaglutide, but the two together clear both. That is why this page treats the comparison as "combination vs monotherapy" rather than "drug A vs drug B."

The one number that reframes everything: they are usually a combo

This is the part no trial table and no competitor page leads with. The most important fact about cagrilintide versus semaglutide is that, in practice, people do not choose between them. They stack them. Cagrilintide was developed and tested largely as a partner for semaglutide, and our community mirrors that exactly: the dominant behavior is co-tracking, not switching. If you only remember one thing from this page, make it this, because it changes the question from "which drug" to "monotherapy or the combination."

Three numbers carry the story, all from ProtocolPlus app data among users tracking these two for weight loss:

• Co-tracking is the headline: ~42% (about 1,532 users) log both. This is far higher than the typical drug pair, and it is the signature of CagriSema. People are not pitting cagrilintide against semaglutide; they are running them together. Co-tracking this high tells you the two are partners, not rivals.
• Adoption is lopsided: semaglutide ~81%, cagrilintide ~19%. Among the 3,648 users tracking one of the two, semaglutide has about 2,964 and cagrilintide about 684. Solo cagrilintide is rare, which fits its investigational, research-only status.
• The switch traffic is small and goes both ways. About 30% of solo-cagrilintide users (roughly 205) later moved to or added semaglutide, while about 10% of semaglutide users (roughly 296) added cagrilintide. Because semaglutide's base is so much larger, the raw net is a slight lean toward cagrilintide (about 91 users), but that mostly reflects people building toward the CagriSema combination, not abandoning semaglutide.

The reason this matters for your decision is simple: if you read a page that frames cagrilintide as a "semaglutide alternative," it is missing how the drug is actually used. Cagrilintide was not built to replace GLP-1; it was built to add a second pathway on top of it. The community data is that intent playing out at scale, with most cagrilintide activity sitting alongside semaglutide rather than instead of it.

The efficacy case: what REDEFINE-1 actually shows

The one-sentence answer: the combination beats either drug alone, and cagrilintide on its own is the weakest of the three. The Phase 3 REDEFINE-1 trial randomized 3,417 adults with obesity (no type 2 diabetes) to CagriSema, cagrilintide alone, semaglutide alone, or placebo, once weekly for 68 weeks. Mean weight loss came in at about 22.7% for CagriSema, about 16.1% for semaglutide, about 11.8% for cagrilintide, and about 2.3% for placebo. That ordering is the whole story: cagrilintide trails semaglutide by itself, but adds enough on top of it to push the combination past both.

The response thresholds make the combination's edge concrete. In REDEFINE-1 about 60% of CagriSema patients reached at least 20% weight loss and about 23% reached 30% or more, a tier semaglutide monotherapy reaches far less often. Earlier evidence agrees on cagrilintide's solo ceiling: in a dose-finding Phase 2 trial, cagrilintide 4.5 mg produced about 10.8% loss at 26 weeks versus about 3.0% for placebo, useful but below what semaglutide delivers alone.

The mechanism explains why stacking works. Semaglutide activates the GLP-1 receptor, which blunts appetite, slows gastric emptying, and improves glucose handling. Cagrilintide is a long-acting amylin analog that acts on amylin receptors (AMY1R and AMY3R) in the brain, a separate satiety pathway tied to amylin, the hormone co-secreted with insulin from the pancreas. Amylin signals fullness and slows stomach emptying through different brain circuits than GLP-1 does, so the two hormones reduce appetite by partly independent routes. Because they hit different receptors, their appetite effects are largely additive rather than redundant, which is the leading explanation for why CagriSema clears either drug alone. It also fits a broader pattern in this drug class: the compounds posting the biggest weight-loss numbers are the ones that recruit more than one appetite pathway at once, whether that is GLP-1 plus GIP (tirzepatide) or GLP-1 plus amylin (CagriSema). That is also why cagrilintide is not a "semaglutide alternative": it is a different class doing a complementary job. For the full pharmacology of each, see the cagrilintide guide and the semaglutide guide.

There is also a useful detail buried in how the arms diverge over time. The combination and the semaglutide arms track closely for the first several weeks, then separate as doses climb, which is consistent with the amylin pathway adding its effect on top of an already-working GLP-1 signal rather than replacing it. In practical terms that means cagrilintide does not make you lose weight faster early on; it raises the ceiling later, once both components are at full dose. That is the same shape the responder data shows: the combination's advantage is concentrated in the higher thresholds, the people pushing past 20% and 25%, not in the first few pounds.

A fair cross-trial caveat: REDEFINE-1's semaglutide arm (~16.1%) ran a touch higher than the classic STEP 1 figure (~14.9%), and you should treat cross-program math as suggestive only because populations, protocols, and time points differ. That caveat is exactly why REDEFINE-1 matters here: same trial, same population, same clock, with all three active arms measured against the same placebo. When cagrilintide alone, semaglutide alone, and the combination are run head to head like this, the ranking is unambiguous, and it is the cleanest evidence available that the value of cagrilintide is additive rather than standalone.

Approval status: the gap that decides it for most people today

The one-sentence answer: only semaglutide is approved and prescribable right now, so for anyone choosing a real treatment today the practical choice is semaglutide, with cagrilintide reachable only inside the combination via trials or research-grade supply. This is the single biggest difference, and it sits above efficacy for most readers.

Semaglutide is FDA-approved as Wegovy for chronic weight management and as Ozempic and Rybelsus for type 2 diabetes, and it carries added approved benefits semaglutide has earned over years of trials, including cardiovascular risk reduction and, more recently, a liver-disease (MASH) indication. Cagrilintide has no standalone approval; it is investigational and, as of 2026, the CagriSema combination is under regulatory review rather than approved. There is no FDA-blessed cagrilintide product to be prescribed, and solo cagrilintide circulates only as unregulated research-grade material. For most people that settles it: you can get semaglutide through a clinician now, and you cannot get approved cagrilintide at all yet.

Is the combination worth it over semaglutide alone?

The one-sentence answer: for maximum weight loss the trial data says yes, the combination adds a meaningful several percentage points over semaglutide alone, but it is not available as an approved product, so "worth it" is currently a question for trial participants and clinician-supervised protocols, not a retail choice. The upside is real; the access is not.

The case for adding cagrilintide is the roughly 6-7 percentage-point gap between CagriSema (~22.7%) and semaglutide alone (~16.1%) in REDEFINE-1, plus the larger share of people reaching the 20% and 30% thresholds. For someone whose semaglutide result has flattened well short of their goal, that gap is the difference between stalling and continuing, which is why the combination is most compelling for plateaued responders rather than first-time starters. The case against, for now, is everything practical: the combination is not approved, it concentrates two drugs' worth of GI side effects, and solo cagrilintide supply is unregulated.

The community pattern reflects this tension precisely. People co-track at high rates because the upside is attractive, but solo cagrilintide adoption stays low because there is no safe, approved way to get it. The honest read of "worth it" is therefore conditional on access more than on biology: the trial benefit is established, but the only legitimate routes to it today are a clinical trial or a clinician-supervised protocol, not a pharmacy. If and when CagriSema is approved, this calculus changes and the question becomes a straightforward cost-versus-magnitude trade like any other add-on; until then, semaglutide alone is the option you can actually obtain and be monitored on, and the combination is best thought of as the trial-backed direction the field is heading rather than a choice you make this month.

Tolerability: GI-dominant for both, the combination stacks it

The one-sentence answer: both are gut-dominant, cagrilintide looks slightly gentler than semaglutide in our reports, but the combination concentrates both drugs' GI load, so CagriSema is not gentler than semaglutide alone. Tolerability rarely picks between the two molecules; it mostly argues for slow titration.

In our community reports the most common effects line up like this: nausea (cagrilintide 38% vs semaglutide 44%), decreased appetite (40% vs 40%), diarrhea (16% vs 30%), constipation (20% vs 24%), and vomiting (18% vs 22%). Cagrilintide skews a little milder across the board in these self-reported numbers, but that is solo cagrilintide; in the REDEFINE-1 combination arm roughly 80% of CagriSema patients reported GI events, mostly mild to moderate, because you are adding two appetite-suppressing mechanisms at once. These are self-reported community frequencies, not trial incidence and not proof of cause, but the direction is consistent: each drug alone is GI-dominant, and together they are more so, not less.

Semaglutide carries the class's serious but rare warnings, including a boxed warning for thyroid C-cell tumors based on rodent data, plus pancreatitis and gallbladder risks; cagrilintide's long-term safety profile is still being established in trials. For the complete tolerability breakdown and red-flag list, read semaglutide side effects. This page does not duplicate them.

Cost and access: no fair comparison exists yet

The one-sentence answer: semaglutide has a real, knowable per-dose cost in our community data (about $19 median), while cagrilintide has none because it is not sold as a product, so cost cannot decide this matchup the way it can for two approved drugs. Access, not price, is the live constraint.

Semaglutide's cost is dominated by coverage and indication: a type 2 diabetes diagnosis routes you to Ozempic, which many plans cover, while obesity alone routes you to Wegovy, covered less consistently. Cagrilintide has no list price, no insurance pathway, and no approved product, so any "cost" you see quoted for it reflects unregulated research-grade vials, which we will not treat as a real comparison. Treat the semaglutide per-dose figure as a directional community signal, not a quote, and treat cagrilintide as priced-on-access: the limiting factor is not dollars but whether you can legitimately obtain it at all.

What about retatrutide and the next generation?

A fair question when choosing today is whether to wait for something stronger. Retatrutide, a triple agonist (GIP, GLP-1, and glucagon), has posted the highest Phase 2 weight-loss figures of any of these compounds and is another investigational option people watch. But like cagrilintide it is not FDA-approved and is available only as research-grade supply, so it is not a like-for-like choice against approved semaglutide. For most people the realistic choice today is still an approved GLP-1 like semaglutide, with the amylin-combination and triple-agonist routes as "later, maybe" rather than "now." We keep those comparisons on their own pages; to weigh approved GLP-1s against each other, see semaglutide vs tirzepatide.

The editorial scorecard (the "why," not the verdict)

The fit-score grouped bars below rate each compound 1 to 5 on six dimensions. Semaglutide leads on evidence, safety, accessibility, speed, and cost, and the two tie on effectiveness, which nets out to a clear overall lead for semaglutide as a standalone choice. That gap is honest and mostly about access and approval, not a claim the amylin pathway is weak; remember the combination, not solo cagrilintide, is where cagrilintide's value lives. The community co-tracking data above, not this scorecard, is the headline signal.

Choose semaglutide if... / Consider cagrilintide (as CagriSema) if...

The decision rarely needs a coin flip, mostly because only one of these is something you can actually get today.

Choose semaglutide if:

• You want an FDA-approved, prescribable option with the deepest track record available today.
• You want a predictable per-dose cost and reliable, regulated supply.
• You are starting weight-loss treatment now and do not want to wait for an investigational combination.
• You value the broader approved benefits semaglutide already carries (cardiovascular risk reduction, MASH).

Consider cagrilintide (as CagriSema) if:

• You are specifically interested in the combination, not cagrilintide alone, and want the highest trial weight loss (~22.7%).
• You have plateaued on semaglutide near its top dose and are exploring the added amylin pathway with a clinician.
• You accept that solo cagrilintide is investigational, research-grade, and the weakest of the three options on its own.
• You are a trial participant or on a clinician-supervised protocol and understand it is not an approved product.

The honest verdict

For anyone choosing a real weight-loss treatment today, semaglutide is the answer, because it is the only one of the two that is approved, prescribable, and supported by years of data. Cagrilintide is not a runner-up so much as a different kind of thing: an investigational add-on whose value shows up only when it is combined with semaglutide as CagriSema, where the trial weight loss (~22.7%) clears semaglutide alone (~16.1%) and cagrilintide alone (~11.8%). The community proves the point by co-tracking the two at about 42%, far more than they switch between them. So the real takeaway is not "pick the winner," it is "semaglutide now, and watch CagriSema." Either way, the drug is a tool inside a clinician-supervised plan, not a decision to make from a comparison page alone.

To make it concrete, here is how the decision usually lands by situation:

• Want a treatment you can get today: semaglutide (approved); cagrilintide is investigational.
• Want the maximum trial weight loss: the CagriSema combination, not cagrilintide alone, and only via a trial or clinician-supervised protocol.
• Considering cagrilintide as a semaglutide replacement: reconsider; alone it loses less than semaglutide (~11.8% vs ~16.1%).
• Plateaued on semaglutide near the top dose: the added amylin pathway (CagriSema) is the trial-backed next step, with a clinician.
• Cost or regulated supply is the priority: semaglutide; cagrilintide has no approved product or insurance pathway.
• Nausea-sensitive and curious about cagrilintide: alone it reads slightly gentler in community reports, but the combination stacks both drugs' GI load.

For brand-specific and adjacent angles, see semaglutide vs tirzepatide. To see where both rank against every option people use, see best peptides for weight loss.

Frequently Asked Questions

Sources

• Novo Nordisk; Garvey WT, et al. "Cagrilintide-Semaglutide (CagriSema) in Adults with Overweight or Obesity" (REDEFINE-1). New England Journal of Medicine, 2025. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2502204
• Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial." The Lancet, 2021;398(10317):2160-2172. DOI 10.1016/S0140-6736(21)01751-7. Retrieved 2026-06-18. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01751-7/abstract
• Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021;384:989-1002. DOI 10.1056/NEJMoa2032183. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• U.S. Food & Drug Administration. "FDA Approves New Drug Treatment for Chronic Weight Management" (Wegovy, semaglutide 2.4 mg). 2021. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). New England Journal of Medicine, 2023. DOI 10.1056/NEJMoa2307563. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
• ProtocolPlus. "Community head-to-head data: cagrilintide vs semaglutide" (head-to-head/cagrilintide__semaglutide.json). First-party app data, 2026. n ~ 3,648 users tracking one of the two for weight loss; ~42% co-track both. Usage and co-tracking signal, not a clinical efficacy verdict.